Loss of exclusivity is the one competitive event in a product's life that is scheduled. The patent expiry and regulatory exclusivity dates are matters of public record, and the finance function has been modelling against them for years. So it is easy to assume there is no intelligence problem here.
There is, and it is this: the date tells you when, and almost nothing about what. Whether a product loses sixty per cent of its revenue in a year or fifteen per cent over four depends on who enters, how many of them, in what channel, against what contracts, and how the originator responds. Those are all forecastable to varying degrees, and the forecast is worth considerably more than the date.
Two legal regimes, two intelligence problems
Small molecules and biologics follow different statutory routes, and the practical consequence for a CI team is that one produces a rich public signal trail and the other mostly does not.
| Small molecule | Biologic | |
|---|---|---|
| Entry route | Abbreviated new drug application under Hatch-Waxman | Abbreviated licensure under the BPCIA |
| Patent listing | Orange Book — public, and changes are observable | Purple Book lists products; patent position is largely established through private exchange |
| Pre-entry signal | Paragraph IV certifications, notice letters, 45-day litigation window, tentative approvals | Sparse — filings are not routinely announced, and the statutory information exchange between parties is confidential |
| First-mover incentive | A period of marketing exclusivity for the first applicant to file a qualifying challenge | No equivalent first-filer exclusivity, which changes entrant behaviour materially |
| Substitution | Automatic at the pharmacy under state law once the product is rated equivalent | Requires an interchangeability designation for pharmacy-level substitution, and is still subject to state law; otherwise a prescriber decision |
| Typical erosion | Fast and steep once multiple entrants are on the market | Slow, highly variable, and driven more by channel and contracting than by the number of entrants |
The statutory detail here changes — exclusivity periods, interchangeability requirements and the associated guidance have all been actively revised in recent years, and there are standing legislative proposals that would change them further. Treat the table as the shape of the problem and verify the current position before relying on any specific mechanism in a forecast.
What to actually track, small molecule
- Orange Book changes. Patents being listed late, or delisted, are informative about the originator's own read on its position.
- Paragraph IV filings and the litigation that follows. The court docket is public and is frequently the earliest reliable confirmation that a specific challenger is serious.
- Tentative approvals. A tentative approval identifies an entrant that has cleared the regulatory bar and is waiting only on exclusivity or litigation — a much stronger signal than an application on file.
- Settlements. Terms are often confidential but the existence of a settlement, and sometimes an agreed entry date, surfaces in company filings and in regulatory disclosure. An agreed entry date is the single most valuable input to the erosion model.
- Authorised generic plans from the originator, which change both the timing and the depth of price decline.
What to actually track, biologic
The signal set is thinner and more inferential, which is precisely why it rewards attention:
- European approvals and filings, which frequently precede US equivalents for the same developer and product, and are more visible.
- Developer disclosure — biosimilar developers are often smaller companies for whom a programme is material and therefore discussed on earnings calls in more detail than an originator would ever volunteer.
- Manufacturing capacity commitments, which are expensive, long-lead and hard to conceal.
- Litigation appearing on the docket, which reveals that the confidential exchange has happened and reached a dispute.
- The statutory notice of commercial marketing, which sets an outer bound on launch timing once given.
- Interchangeability status, because it governs whether substitution can happen without a prescriber in the loop.
The asymmetry is the point. For a small molecule, a well-run CI function can usually name the likely entrants and a plausible entry window years ahead. For a biologic it frequently cannot, and the honest deliverable is a set of scenarios with the observable triggers that would tell you which one you are in. Presenting a biologic LOE forecast with the same confidence as a small-molecule one is a misrepresentation of what is knowable.
Why biosimilar erosion is not generic erosion
The most expensive mistake in this area is applying a small-molecule erosion curve to a biologic because it is the curve the organisation has always used. The mechanisms are genuinely different:
- Substitution is not automatic. Without interchangeability, a switch requires a prescriber to make it, which introduces inertia that no price difference fully overcomes.
- Channel decides who has leverage. A product bought and billed in a provider setting erodes according to provider and payer economics; one sitting in the pharmacy benefit erodes according to formulary decisions. These produce different curves for the same clinical situation.
- Incumbent contracting can delay entry economics. An originator with volume-based agreements in place can make it unattractive for a payer to move even when a cheaper biosimilar exists — a dynamic usually discussed as the rebate wall, and one that has drawn sustained regulatory and legal attention.
- Entry is expensive, so there are fewer entrants. Biosimilar development costs orders of magnitude more than a generic, which limits how many competitors appear and how far price falls.
- The originator has more room to respond — presentation changes, device improvements, subcutaneous reformulation, patient support and contracting all shift volume in ways a small-molecule originator cannot replicate.
The practical implication: an erosion forecast for a biologic that is not built on an explicit view of channel, contract exposure and interchangeability status is a number with no mechanism behind it.
What the LOE team needs, and when
A defensible LOE brief
- Named likely entrants, with the evidence for each and an honest confidence level — not a count
- An entry window as a range, with the events that would narrow it
- The mechanism of erosion for this specific product — substitution route, channel, contract exposure
- Scenarios rather than a curve, each with observable triggers so the team knows which one it is in as it unfolds
- The originator response options that are actually available, and what competitors have done in analogous situations
Timing matters as much as content. Lifecycle decisions — reformulation, next-generation development, indication expansion, contracting posture — have lead times measured in years. Intelligence delivered eighteen months before entry arrives after the decisions it should have informed have already been taken.
Common mistakes
Treating the patent expiry as the event. The commercially relevant date is first entry, which may be considerably earlier through settlement or later through litigation or manufacturing delay.
Modelling from an analogue without checking the mechanism. Two biologics with similar revenue and similar entrant counts can erode completely differently if one is in the pharmacy benefit and the other is provider-administered. Analogue selection should be on mechanism, not on size.
Stopping at launch. The most useful monitoring happens in the eighteen months after entry, when the actual curve is diverging from the forecast and there is still time to respond.
Ignoring ex-US. Different exclusivity regimes and procurement models mean erosion frequently starts earlier and behaves differently outside the US, and that experience is a genuine forward indicator for the US market.